Highlights Scinai Immunotherapeutics Ltd.

Equities

BVXV

US09073Q3039

Delayed Nasdaq Other stock markets 01:30:00 2024-07-03 pm EDT			5-day change	1st Jan Change
3.125 ^USD	+4.87%		-2.34%	-47.51%

Jul. 02	Scinai Immunotherapeutics Ltd. Provides Earnings Guidance for 2024	CI
Jul. 02	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Scinai Immunotherapeutics Ltd. Provides Earnings Guidance for 2024	Jul. 02	CI
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Jul. 02	CI
ADRs End Flat; Alarum Technologies Climbs 26%	Jun. 27	DJ
Top Premarket Gainers	Jun. 17	MT
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	May. 15	CI
Scinai Immunotherapeutics Plans 1-for-10 Reverse Stock Split to Avoid Possible Delisting	May. 06	MT
Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls	Apr. 08	MT
Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services	Apr. 08	CI
Scinai Immunotherapeutics Regains Compliance With Nasdaq's Shareholder Equity Rule	Nov. 20	MT
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
BiondVax Pharmaceuticals Ltd. Signs Exclusive License Agreement for Development and Commercialization of A Novel Anti-II-17 Antibody for Treatment of Autoimmune and Inflammatory Diseases Including Psoriasis	23-06-05	CI
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Biondvax Pharmaceuticals Ltd. Announces Additional Results in Preclinical Proof-of-Concept Study of its Innovative Inhaled NanoAb COVID-19 Drug	23-01-23	CI
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study	23-01-06	CI
BiondVax Pharmaceuticals Regains Compliance with Nasdaq Listing Rules	22-12-12	MT
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-30	CI
BiondVax Pharmaceuticals Ltd. Reports Successful Results in Preclinical in Vivo Study of its Innovative Inhaled COVID-19 NanoAb Therapy	22-11-29	CI
Biondvax Pharmaceuticals Ltd. Announces Strategic Research Collaboration with Max Planck and University Medical Center Göttingen	22-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Scinai Immunotherapeutics Ltd.

Equities

BVXV

US09073Q3039

Highlights

Filters